Altering immune tolerance in Alzheimer disease
改变阿尔茨海默病的免疫耐受性
基本信息
- 批准号:9979733
- 负责人:
- 金额:$ 23.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-08-01 至 2022-05-31
- 项目状态:已结题
- 来源:
- 关键词:Abeta clearanceAgeAgonistAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAlzheimer&aposs disease pathologyAlzheimer&aposs disease therapyAmyloid beta-ProteinAnimal ModelB-LymphocytesBehavioralBrainC Type Lectin ReceptorsCD14 geneCandida albicansCell WallCell physiologyCellsCerebrumChemicalsChronicClinicalCognitive deficitsComplexDepositionDevelopmentDisease ProgressionEndotoxinsEpigenetic ProcessEtiologyEuglena gracilisExposure toGene ExpressionGene MutationGenetic RecombinationGenetic RiskGenetic studyGoalsGrowth FactorHippocampus (Brain)ImmuneImmune ToleranceImmunityImmunologic MemoryImmunologyIn VitroInflammationInflammation MediatorsInflammatoryIngestionInjectionsInnate Immune ResponseInnate Immune SystemLate Onset Alzheimer DiseaseLigandsLigationLipid ALipopolysaccharidesMeasuresMetabolicMicrogliaMolecularMusNerve DegenerationNeuraxisNeurofibrillary TanglesNeuronal PlasticityNeuronsPTPRC genePathogenesisPathologicPathway interactionsPatientsPattern recognition receptorPhagocytesPhagocytosisPhenotypePhysiologicalPlayPreventionPreventivePreventive measureProductionResistanceRoleSenile PlaquesSignal TransductionT-LymphocyteTLR2 geneTLR4 geneTLR6 geneTestingTherapeuticTissuesToll-like receptorsTrainingTranscriptional Activationadaptive immunitybeta-Glucansbrain parenchymachemokinecytokinecytotoxicdectin 1hyperphosphorylated tauimprovedin vivomacrophagemicroorganismmonocytemouse modelneuroinflammationneuronal survivalpathogenprotein aggregationreceptorresponserisk varianttau Proteinstranscription factortransgenic model of alzheimer diseasewasting
项目摘要
Altering immune tolerance in Alzheimer disease
Amyloid plaques composed of deposits of abnormally aggregated amyloid β-protein (Aβ) and neurofibrillary
tangles (NFTs) consisting of abnormal aggregates of hyperphosphorylated tau protein in the brain are two main
pathological changes in patients with Alzheimer’s disease (AD). Amyloid plaques and NFTs are accompanied
with chronic inflammation characterized by activated microglia and increased cytokines. The causes for the vast
majority of AD cases are unknown and satisfactory therapeutic and preventive measures for AD are unavailable.
Therefore, an urgent need exists to identify the molecular pathways that can modulate the progression of the
vast majority of AD cases for development of preventive and therapeutic measures. Many lines of evidence
support the notion that activated microglia, innate immune cells in the central nervous system, play pivotal, dual
roles in AD progression: either clearing Aβ deposits by phagocytosis and promoting neuron survival and plasticity
or releasing cytotoxic chemicals and inflammatory cytokines, exacerbating Aβ load and causing
neurodegeneration. Activating microglia with a beneficial phenotype should have clinically vital importance in AD
therapy and prevention. C-type lectin receptors including dectin-1 and toll-like receptors (TLRs) including TLR4
are classes of pattern-recognition receptors in the innate immune system. One of the important roles of these
receptors is to activate microglia in response to pathogens and damaged host cells and to clear pathogens,
damaged tissues, and accumulated wastes. Activation of microglia through certain TLRs can markedly boost
ingestion and clearance of Aβ. Indeed, treatments of AD mouse models with certain TLR agonists activate
microglia, decrease cerebral Aβ deposits and NFTs, and improve cognitive deficits. However, prolonged
exposure to certain TLR agonists, such as lipopolysaccharide (LPS), induce hyporesponsiveness to subsequent
TLR agonist challenges (endotoxin/TLR tolerance), leading to immune paralysis. Because Aβ aggregates are a
TLR agonist, we hypothesize that chronic exposure of microglia to Aβ aggregates induces Aβ/TLR tolerance,
leading to decreased clearance of Aβ aggregates and reduced neuronal survival and plasticity in AD and its
animal models. We found that an AD mouse model becomes hypo-responsive to a TLR4 agonist, LPS, after
cerebral Aβ deposition (tolerance). Activation of dectin-1 signaling reverses or counteracts LPS tolerance in
monocytes. We hypothesize that dectin-1 signaling enhances clearance of Aβ deposits and ameliorates cognitive
deficits in an AD mouse model by counteracting and reversing “LPS/Aβ tolerance”. This hypothesis will be tested
by carrying out the following aims. In Aim 1, we will produce a dectin-1-deficient (clec7a-/-) AD mouse model and
determine its effects on AD-pathology and behavioral functions. In Aim 2, we will inject a dectin-1 ligand into the
hippocampi of dectin-1-deficient and -sufficient AD mouse models and determine its effects on AD pathology
and behavioral functions. The long term goals of this study are to determine the role of dectin-1 signaling in the
AD pathogenesis and to develop new preventive and therapeutic strategies for AD.
改变阿尔茨海默病的免疫耐受
淀粉样斑块由异常聚集的淀粉样β蛋白(Aβ)和神经胶质细胞沉积组成,
由脑中过度磷酸化的tau蛋白的异常聚集体组成的缠结(NFT)是两种主要的
阿尔茨海默病(AD)患者的病理变化。淀粉样斑块和NFT伴随
慢性炎症的特征是小胶质细胞活化和细胞因子增加。造成这种情况的原因
大多数AD病例尚不清楚,且尚无满意的AD治疗和预防措施。
因此,迫切需要鉴定可以调节肿瘤进展的分子途径。
绝大多数AD病例的预防和治疗措施的发展。多方面证据
支持这样的观点,即激活的小胶质细胞,中枢神经系统中的先天免疫细胞,
在AD进展中的作用:通过吞噬作用清除Aβ沉积,促进神经元存活和可塑性
或释放细胞毒性化学物质和炎性细胞因子,加剧Aβ负荷,
神经变性激活具有有益表型的小胶质细胞在AD中具有重要的临床意义
治疗和预防。C型凝集素受体,包括dectin-1和Toll样受体(TLR),包括TLR 4
是先天免疫系统中的模式识别受体。其中一个重要的作用是
受体的作用是激活小胶质细胞以响应病原体和受损的宿主细胞并清除病原体,
受损的组织和累积的废物。通过某些TLR激活小胶质细胞可以显著增强
Aβ的摄取和清除。事实上,用某些TLR激动剂治疗AD小鼠模型激活了
小胶质细胞,减少脑Aβ沉积和NFT,并改善认知缺陷。然而,长期
暴露于某些TLR激动剂,例如脂多糖(LPS),诱导对随后的TLR激动剂的低反应性。
TLR激动剂激发(内毒素/TLR耐受性),导致免疫麻痹。因为Aβ聚集体是一种
TLR激动剂,我们假设小胶质细胞长期暴露于Aβ聚集体诱导Aβ/TLR耐受,
导致AD患者Aβ聚集体清除率降低,神经元存活率和可塑性降低,
动物模型我们发现,AD小鼠模型对TLR 4激动剂LPS的反应性降低,
大脑Aβ沉积(耐受性)。dectin-1信号的激活逆转或抵消LPS耐受,
单核细胞我们假设dectin-1信号通路增强了Aβ沉积物的清除,并改善了认知功能。
通过抵消和逆转“LPS/Aβ耐受性”来改善AD小鼠模型中的缺陷。这一假设将得到检验
实现以下目标。在目标1中,我们将产生dectin-1缺陷型(clec 7a-/-)AD小鼠模型,
确定其对AD病理学和行为功能的影响。在目标2中,我们将dectin-1配体注射到
Dectin-1缺陷和不足AD小鼠模型的细胞凋亡,并确定其对AD病理学的影响
和行为功能。本研究的长期目标是确定dectin-1信号转导在细胞凋亡中的作用。
探讨AD的发病机制,并提出新的防治策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ken-ichiro Fukuchi其他文献
Ken-ichiro Fukuchi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ken-ichiro Fukuchi', 18)}}的其他基金
Role of MyD88 signaling in systemic inflammation and Alzheimer disease
MyD88 信号在全身炎症和阿尔茨海默病中的作用
- 批准号:
10456872 - 财政年份:2021
- 资助金额:
$ 23.99万 - 项目类别:
Role of MyD88 signaling in systemic inflammation and Alzheimer disease
MyD88 信号在全身炎症和阿尔茨海默病中的作用
- 批准号:
10314883 - 财政年份:2021
- 资助金额:
$ 23.99万 - 项目类别:
Role of MyD88 signaling in systemic inflammation and Alzheimer disease
MyD88 信号在全身炎症和阿尔茨海默病中的作用
- 批准号:
10611489 - 财政年份:2021
- 资助金额:
$ 23.99万 - 项目类别:
Role of extracellular vesicles in the high-fat diet-induced risk of Alzheimer disease
细胞外囊泡在高脂肪饮食诱发的阿尔茨海默病风险中的作用
- 批准号:
9385535 - 财政年份:2017
- 资助金额:
$ 23.99万 - 项目类别:
Role of diet-induced miR-34a in Alzheimer disease and dementia
饮食诱导的 miR-34a 在阿尔茨海默病和痴呆中的作用
- 批准号:
9225329 - 财政年份:2017
- 资助金额:
$ 23.99万 - 项目类别:
Role of the MyD88-independent pathway in Alzheimers disease
MyD88 独立通路在阿尔茨海默病中的作用
- 批准号:
8511261 - 财政年份:2013
- 资助金额:
$ 23.99万 - 项目类别:
Role of the MyD88-independent pathway in Alzheimers disease
MyD88 独立通路在阿尔茨海默病中的作用
- 批准号:
8676620 - 财政年份:2013
- 资助金额:
$ 23.99万 - 项目类别:
Catalytic and non-catalytic Ig gene delivery for Alzheimer's disease
阿尔茨海默病的催化和非催化 Ig 基因递送
- 批准号:
7963696 - 财政年份:2010
- 资助金额:
$ 23.99万 - 项目类别:
Catalytic and non-catalytic Ig gene delivery for Alzheimer's disease
阿尔茨海默病的催化和非催化 Ig 基因递送
- 批准号:
8081811 - 财政年份:2010
- 资助金额:
$ 23.99万 - 项目类别:
Innate immunity in Alzheimer's disease: Role of toll-like receptor signaling
阿尔茨海默氏病的先天免疫:Toll 样受体信号传导的作用
- 批准号:
7904117 - 财政年份:2009
- 资助金额:
$ 23.99万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 23.99万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 23.99万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 23.99万 - 项目类别:
Fellowship
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 23.99万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 23.99万 - 项目类别:
Continuing Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 23.99万 - 项目类别:
Standard Grant
The economics of (mis)information in the age of social media
社交媒体时代(错误)信息的经济学
- 批准号:
DP240103257 - 财政年份:2024
- 资助金额:
$ 23.99万 - 项目类别:
Discovery Projects
How age & sex impact the transcriptional control of mammalian muscle growth
你多大
- 批准号:
DP240100408 - 财政年份:2024
- 资助金额:
$ 23.99万 - 项目类别:
Discovery Projects
Supporting teachers and teaching in the age of Artificial Intelligence
支持人工智能时代的教师和教学
- 批准号:
DP240100111 - 财政年份:2024
- 资助金额:
$ 23.99万 - 项目类别:
Discovery Projects
Enhancing Wahkohtowin (Kinship beyond the immediate family) Community-based models of care to reach and support Indigenous and racialized women of reproductive age and pregnant women in Canada for the prevention of congenital syphilis
加强 Wahkohtowin(直系亲属以外的亲属关系)以社区为基础的护理模式,以接触和支持加拿大的土著和种族育龄妇女以及孕妇,预防先天梅毒
- 批准号:
502786 - 财政年份:2024
- 资助金额:
$ 23.99万 - 项目类别:
Directed Grant